Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr175 Inhibitors

Olr175 inhibitors represent a class of chemical compounds characterized by their ability to specifically modulate the function of the olfactory receptor 175 (Olr175). Olr175 is a G-protein-coupled receptor (GPCR) that is predominantly expressed in the olfactory system of various species, including humans and rodents. This receptor is part of a vast family of olfactory receptors that detect and transduce chemical signals into electrical signals, contributing to the perception of odors. Olr175 inhibitors are structurally diverse, reflecting the complexity of the receptor's ligand-binding domain and the variety of chemical structures that can interact with it. These inhibitors typically function by binding to the active site or an allosteric site of the receptor, thereby preventing the binding of natural odorant molecules or disrupting the normal signal transduction pathway. The design and synthesis of Olr175 inhibitors often involve detailed molecular modeling and structure-activity relationship (SAR) studies to enhance their specificity and potency.

The chemical composition of Olr175 inhibitors can vary widely, but they generally include small organic molecules that feature functional groups capable of forming specific interactions with the receptor, such as hydrogen bonds, hydrophobic interactions, and van der Waals forces. These compounds often include aromatic rings, heterocyclic moieties, and polar substituents that are critical for high-affinity binding. Advanced synthetic techniques, including combinatorial chemistry and high-throughput screening, are frequently employed to discover novel Olr175 inhibitors. These inhibitors are of particular interest in research focused on understanding the molecular mechanisms of olfaction and the role of specific olfactory receptors in sensory processing. Studies on Olr175 inhibitors contribute to the broader field of chemosensory research by providing insights into receptor-ligand interactions, receptor activation, and the structural basis of odorant recognition. Additionally, these inhibitors serve as valuable tools in dissecting the functional roles of olfactory receptors in non-olfactory tissues, offering a window into the diverse physiological roles these receptors may play.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Targets multiple kinases, could disrupt cell signaling in cancer cells.

Cobimetinib

934660-93-2sc-507421
5 mg
$270.00
(0)

MEK inhibitor, may interfere with MAPK/ERK signaling in tumor cells.

Selumetinib

606143-52-6sc-364613
sc-364613A
sc-364613B
sc-364613C
sc-364613D
5 mg
10 mg
100 mg
500 mg
1 g
$29.00
$82.00
$420.00
$1897.00
$3021.00
5
(1)

MEK1/2 inhibitor, could block cell proliferation in certain cancers.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

Inhibits MET, VEGFR, and AXL, may impact tumor growth and metastasis.

Neratinib

698387-09-6sc-364549
sc-364549A
sc-364549B
sc-364549C
sc-364549D
5 mg
25 mg
100 mg
500 mg
1 g
$92.00
$214.00
$383.00
$755.00
$1250.00
4
(1)

Pan-HER inhibitor, potentially impacting HER2-positive breast cancer cells.

Lenvatinib

417716-92-8sc-488530
sc-488530A
sc-488530B
5 mg
25 mg
100 mg
$182.00
$661.00
$1690.00
3
(0)

Targets VEGF receptors, could disrupt angiogenesis and tumor growth.

Regorafenib

755037-03-7sc-477163
sc-477163A
25 mg
50 mg
$320.00
$430.00
3
(0)

Inhibits multiple kinases, may affect tumor growth and angiogenesis.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Targets VEGF and PDGF receptors, potentially affecting tumor angiogenesis.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Inhibits VEGF receptors, could impair angiogenesis in renal cell carcinoma.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

Inhibits VEGFR, EGFR, and RET, may influence growth of medullary thyroid cancer.